



September 2022

Dear Huntington's disease community,

We are pleased to share an update with you regarding SELECT-HD, our Phase 1b/2a clinical trial studying WVE-003 for people with Huntington's disease. WVE-003 is an investigational antisense oligonucleotide (ASO) designed to selectively reduce mutant huntingtin (mHTT) protein while sparing healthy, or wild-type, huntingtin (wtHTT) protein.

#### **SELECT-HD Update**

On September 20<sup>th</sup>, we announced initial data from the SELECT-HD trial. The data suggests that WVE-003 appeared generally safe and well-tolerated for study participants who received single doses up to 90 mg. Additionally, for the study participants in the 30 and 60 mg cohorts, these initial data suggest that WVE-003 is hitting its target, appearing to lower mutant huntingtin protein while potentially not reducing wild-type huntingtin. At the time of analysis, none of the patients in the 90 mg cohort had reached day 85 so this cohort was not included in the biomarker analysis. It should be noted that it cannot be concluded that WVE-003 is efficacious, and benefit/risk must still be established through continuation of this, and other studies.

#### **What happens next?**

SELECT-HD is an adaptive trial, which means there is an independent committee that reviews the data throughout the trial and decides what the next dose will be and how often the drug should be administered. Based on the recommendation of the committee, Wave is adapting the SELECT-HD clinical trial to expand the single dose cohorts and will extend the follow-up period to enable further assessments beyond 85 days.

More details about the SELECT-HD trial can also be found on [clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT05032196) ([NCT05032196](https://clinicaltrials.gov/ct2/show/study/NCT05032196)) and should be discussed with your physician.

#### **Our Gratitude**

We are grateful to the HD community, including the SELECT-HD participants, study sites, and advisors, for their continued partnership and support of this program. From our conversations and collaborations, we know firsthand of the commitment and determination of this community, which inspires and motivates us every day as we continue our mission toward discovering meaningful treatments for HD. We look forward to continuing to expand this study and sharing additional data next year.

Sincerely,

*Chelley Casey*

[Chelley Casey \(Nov 21, 2022 14:58 EST\)](#)

Chelley Casey, VP, Head of Patient Advocacy

On behalf of the team at Wave Life Sciences